MEDIROM Healthcare Technologies (MRM) AI Stock Analysis

MEDIROM Healthcare Technologies

(NASDAQ:MRM)

Select Model

Rating:48Neutral

Price Target:$1.50▲(354.55% Upside)

Action:reiterated

Date:11/04/25

Severe financial weaknesses—including unsustainable cash burn and high debt—are the primary drag. Undervaluation offers limited support, while technicals show mixed near-term signals amid a longer-term uptrend.

Positive Factors

Recurring & Diversified Revenue ModelMEDIROM’s mix of tiered telemedicine subscriptions, product sales and service agreements builds recurring and diversified revenues. That business model provides predictable cash inflows, cross-sell opportunities and resilience versus single-product firms, supporting steadier medium-term growth.

Negative Factors

High Leverage / Low Equity RatioA low equity ratio and material debt-to-equity indicate heavy reliance on debt financing. Elevated leverage raises interest expense and refinancing sensitivity, limiting strategic flexibility and increasing solvency risk if operational performance weakens over the next several quarters.

MEDIROM Healthcare Technologies (MRM) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $1.69M
Dividend Yield: ―
Average Volume (3M): 146.54K
Price to Earnings (P/E): -0.7
Beta (1Y): 1.20
Revenue Growth: ―
EPS Growth: ―
Country: US
Employees: 334
Sector: Consumer Cyclical
Sector Strength: 61
Industry: Personal Products & Services

MEDIROM Healthcare Technologies Business Overview & Revenue Model

Company Description

MEDIROM Healthcare Technologies Inc. (MRM) is a Japanese company that offers comprehensive healthcare solutions, operating through two primary divisions: Relaxation Salon and Digital Preventative Healthcare. The Relaxation Salon segment oversees a ne...

How the Company Makes Money

MEDIROM Healthcare Technologies generates revenue through multiple channels, including subscription fees for its telemedicine services, sales of wellness and diagnostic products, and partnerships with healthcare providers and institutions. The compan...

MEDIROM Healthcare Technologies Financial Statement Overview

Summary

Critical challenges in cash flow (-¥1.90B FCF), high leverage (debt-to-equity 4.24), and thin profitability (1.8% net margin) outweigh strong revenue growth (21.6%) and margin improvements. Urgent financial restructuring needed.

Income Statement

45Neutral

Balance Sheet

25Negative

Cash Flow

15Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.06B	8.30B	6.83B	6.95B	5.41B	3.34B
Gross Profit	1.47B	2.25B	1.57B	1.90B	1.42B	428.95M
EBITDA	-370.14M	387.50M	310.08M	373.63M	-276.29M	-551.16M
Net Income	-111.71M	148.76M	115.05M	148.97M	-990.73M	-539.17M
Balance Sheet
Total Assets	5.83B	8.09B	6.85B	6.75B	5.75B	5.71B
Cash, Cash Equivalents and Short-Term Investments	144.65M	335.56M	132.85M	605.95M	377.12M	1.47B
Total Debt	3.57B	3.96B	3.65B	3.23B	2.79B	2.56B
Total Liabilities	6.19B	6.90B	6.63B	6.81B	5.96B	5.22B
Stockholders Equity	-363.20M	933.27M	210.88M	-59.38M	-208.34M	491.26M
Cash Flow
Free Cash Flow	-905.71M	-1.90B	-767.58M	-806.44M	-652.88M	-439.98M
Operating Cash Flow	-807.42M	-1.33B	-631.74M	-685.70M	-557.23M	-366.42M
Investing Cash Flow	311.09M	361.39M	-328.58M	580.44M	-83.94M	-139.60M
Financing Cash Flow	560.88M	1.19B	461.21M	340.10M	-427.95M	1.43B

MEDIROM Healthcare Technologies Technical Analysis

Technical Analysis SentimentNegative

Last Price0.33

Price Trends

50DMA0.66Negative

100DMA0.84Negative

200DMA1.05Negative

Market Momentum

MACD-0.09Negative

RSI22.89Positive

STOCH25.83Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MRM, the sentiment is Negative. The current price of 0.33 is below the 20-day moving average (MA) of 0.41, below the 50-day MA of 0.66, and below the 200-day MA of 1.05, indicating a bearish trend. The MACD of -0.09 indicates Negative momentum. The RSI at 22.89 is Positive, neither overbought nor oversold. The STOCH value of 25.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MRM.

MEDIROM Healthcare Technologies Risk Analysis

MEDIROM Healthcare Technologies disclosed 60 risk factors in its most recent earnings report. MEDIROM Healthcare Technologies reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

2 New Risks

1.ADSs representing our common shares are listed on the Nasdaq Capital Market. As such, we must meet the Nasdaq Capital Market's continued listing requirements and other Nasdaq rules, or we may risk delisting. Delisting could negatively affect the price of our ADSs, which could make it more difficult for us to sell securities in a financing and for you to sell your ADSs.Q4, 2022

2.Sale of our salons could depend heavily on a number of factors, and as a result, our annual revenue from sale of salons may vary from year on year.Q4, 2022

MEDIROM Healthcare Technologies Peers Comparison

Overall Rating

UnderperformOutperform

Sector (61)

Financial Indicators

MRM against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61Neutral	$18.38B	12.79	-2.54%	3.03%	1.52%	-15.83%
RGS	58Neutral	$74.17M	10.75	3.66%	―	6.83%	-94.25%
MRM	48Neutral	$2.61M	-0.67	-68.38%	―	―	―
EJH	40Neutral	$4.19M	-0.57	1.38%	―	-1.57%	―

* Consumer Cyclical Sector Average

Performance Comparison

MRM and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
MRM	Medirom Healthcare Technologies, Inc.	0.33	-1.59	-82.81%
RGS	Regis Corporation	29.67	0.17	0.56%
EJH	E-Home Household Service Holdings Ltd.	1.31	-23.19	-94.65%

MEDIROM Healthcare Technologies Corporate Events

MEDIROM MOTHER Labs Triples REMONY Deployment with New JGSDF 8th Division Order

Jun 25, 2026

On June 25, 2026, MEDIROM MOTHER Labs, a subsidiary of MEDIROM Healthcare Technologies, announced that it received an additional order from the Japan Ground Self-Defense Force’s 8th Division for its REMONY remote health monitoring system, which...

MEDIROM Faces Nasdaq Non-Compliance Notice Over Delayed 20-F Filing

May 29, 2026

MEDIROM Healthcare Technologies Inc., a Japan-based operator of roughly 300 Re.Ra.Ku wellness salons and a developer of HealthTech solutions such as the Lav training app and MOTHER Bracelet smart tracker, straddles the consumer wellness and remote mo...

MEDIROM Posts Q1 2026 KPIs as Hybrid Staffing and World ID Partnership Gain Traction

May 28, 2026

MEDIROM Healthcare Technologies reported first-quarter 2026 performance on May 28, 2026, highlighting a salon business that continues to command premium pricing, with average revenue per customer rising 7.7% year on year to 7,822 yen, well above the...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 04, 2025

MEDIROM Healthcare Technologies AI Stock Analysis